EntRel|03|39||||236|2|||||||||||||||159..234|1|LUTHER BURBANK CROSS-BRED PLANTS to produce the billion-dollar Idaho potato||||||||236..337|2|Bioengineers set out to duplicate that feat -- scientifically and commercially -- with new life forms|||||||||||||
Implicit|03|39||||469|4||then||Temporal.Asynchronous.Precedence||||Wr|Comm|Null|Null||||341..467|3|In 1953, James Watson and his colleagues unlocked the double helix of DNA (deoxyribonucleic acid), the genetic key to heredity|Inh|Null|Null|Null||||469..647|4|Twenty years later, two California academics, Stanley Cohen and Herbert Boyer, made "recombinant" DNA, transplanting a toad's gene into bacteria, which then reproduced toad genes|Inh|Null|Null|Null|||||||||
Explicit|03|39|621..625|4,3,3,1,2,1,2,1,0|then|||then|||Temporal.Asynchronous.Precedence||||Wr|Comm|Null|Null||||572..613|4,3,3,0;4,3,3,1,0;4,3,3,1,1;4,3,3,1,2,0;4,3,3,1,2,1,0;4,3,3,1,2,1,1|transplanting a toad's gene into bacteria|Inh|Null|Null|Null||||615..620;626..647|4,3,3,1,2,1,2,0;4,3,3,1,2,1,2,1,1;4,3,3,1,2,1,2,1,2|which reproduced toad genes|Inh|Null|Null|Null|||||||||
Explicit|03|39|651..655|5,0,0|When|||when|||Temporal.Synchrony||||Wr|Comm|Null|Null||||737..758|5,1;5,2;5,3;5,4|they saw dollar signs|Inh|Null|Null|Null||||656..735|5,0,1|Boyer met Robert Swanson, an M.I.T.-trained chemist-turned-entrepreneur in 1976|Inh|Null|Null|Null|||||||||
Implicit|03|39||||760|6||so||Contingency.Cause.Result||||Wr|Comm|Null|Null||||651..758|5|When Boyer met Robert Swanson, an M.I.T.-trained chemist-turned-entrepreneur in 1976, they saw dollar signs|Inh|Null|Null|Null||||760..839|6|With $500 apiece and an injection of outside capital, they formed Genentech Inc|Inh|Null|Null|Null|||||||||
Implicit|03|39||||841|7||and|thus|Temporal.Synchrony||Contingency.Cause.Result||Wr|Comm|Null|Null||||760..839|6|With $500 apiece and an injection of outside capital, they formed Genentech Inc|Inh|Null|Null|Null||||841..874|7|Commercial gene-splicing was born|Inh|Null|Null|Null|||||||||
AltLex|03|39|965..986|9,0,0,0;9,0,0,1,1,1,0;9,0,0,1,1,1,1,0;9,0,0,1,1,1,1,1,0|The next to be cloned||||||Temporal.Asynchronous.Precedence||||Wr|Comm|Null|Null||||878..963|8|Genentech's first product, a brain protein called somatostatin, proved its technology|Inh|Null|Null|Null||||965..1132|9|The next to be cloned, human insulin, had market potential and Genentech licensed it to Eli Lilly, which produced 80% of the insulin used by 1.5 million U.S. diabetics|Inh|Null|Null|Null|||||||||
Explicit|03|39|1024..1027|9,1|and|||and|||Expansion.Conjunction|Contingency.Cause.Result|||Wr|Comm|Null|Null||||965..1023|9,0|The next to be cloned, human insulin, had market potential|Inh|Null|Null|Null||||1028..1132|9,2|Genentech licensed it to Eli Lilly, which produced 80% of the insulin used by 1.5 million U.S. diabetics|Inh|Null|Null|Null|||||||||
Explicit|03|39|1386..1397|12,0|Nonetheless|||nonetheless|||Comparison.Concession.Contra-expectation||||Wr|Comm|Null|Null||||1228..1384|11|At the time, Genentech had only one profitable year behind it (a modest $116,000 on revenue of $2.6 million in 1979) and no product of its own on the market|Inh|Null|Null|Null||||1399..1491|12,1;12,2;12,3;12,4|the $36 million issue they floated in 1980 opened at $35 and leaped to $89 within 20 minutes|Inh|Null|Null|Null|||||||||
Explicit|03|39|1563..1575|14,0,0,1,1|for instance|||for instance|||Expansion.Instantiation||||Wr|Comm|Null|Null||||1495..1544|13|The trip from the test tube was not without snags|Inh|Null|Null|Null||||1546..1561;1577..1738|14,0,0,0;14,0,0,1,0;14,0,0,1,2;14,0,0,2;14,0,0,3;14,0,1;14,1;14,2;14,3;14,4;14,5|Boyer and Cohen both still university researchers, had to be talked into applying for a patent on their gene-splicing technique -- and then the Patent Office refused to grant it|Inh|Null|Null|Null|||||||||
Explicit|03|39|1692..1695|14,2|and|||and|||Expansion.Conjunction||||Wr|Comm|Null|Null||||1546..1688|14,0|Boyer and Cohen, for instance, both still university researchers, had to be talked into applying for a patent on their gene-splicing technique|Inh|Null|Null|Null||||1696..1738|14,3;14,4;14,5|then the Patent Office refused to grant it|Inh|Null|Null|Null|||||||||
Explicit|03|39|1696..1700|14,3|then|||then|||Temporal.Asynchronous.Precedence||||Wr|Comm|Null|Null||||1546..1688|14,0|Boyer and Cohen, for instance, both still university researchers, had to be talked into applying for a patent on their gene-splicing technique|Inh|Null|Null|Null||||1692..1695;1701..1738|14,2;14,4;14,5|and the Patent Office refused to grant it|Inh|Null|Null|Null|||||||||
Explicit|03|39|1755..1762|15,2|in turn|||in turn|||Temporal.Asynchronous.Precedence||||Wr|Comm|Null|Null||||1692..1738|14,2;14,3;14,4;14,5|and then the Patent Office refused to grant it|Inh|Null|Null|Null||||1740..1753;1764..1802|15,0;15,1;15,3;15,4,0;15,4,1,0;15,4,1,1;15,4,1,2;15,4,1,3;15,5|That judgment was reversed by the U.S. Supreme Court|Inh|Null|Null|Null|||||||||
Implicit|03|39||||1976|17||for example||Expansion.Instantiation||||Wr|Comm|Null|Null||||1916..1974|16|Gene-splicing now is an integral part of the drug business|Inh|Null|Null|Null||||1976..2058|17|Genentech's 1988 sales were $335 million, both from licensing and its own products|Inh|Null|Null|Null|||||||||
